Search Within

Virginia Klimek

Formats
  1. Meeting Abstract (78)
  2. Journal Article (64)
  3. Editorial (2)
  4. Research Letter (2)
  5. Book Section (1)
Groups
  1. Adult Leukemia (147)
  2. Center for Hematologic Malignancies (147)
  3. Department of Medicine (147)
  4. Hematologic Malignancies, Division of (147)
  5. GSK Faculty (44)
  6. Epidemiology and Biostatistics (36)

More Groups

People
  1. Stephen Nimer (30)
  2. Sean Devlin (26)
  3. Martin Tallman (22)
  4. Ross Levine (21)
  5. Stephen Chung (18)
  6. Elli Papaemmanuil (14)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (3)
  4. 2021 (5)
  5. 2020 (8)
  6. 2019 (14)

More Years

Publications
  1. Blood (54)
  2. Leukemia Research (10)
  3. Journal of Clinical Oncology (9)
  4. Haematologica (8)
  5. Bone Marrow Transplantation (4)
  6. British Journal of Haematology (3)

More Publications

Publishers
  1. American Society of Hematology (54)
  2. Nature Publishing Group (17)
  3. American Society of Clinical Oncology (10)
  4. Elsevier Ltd (10)
  5. Ferrata Storti Foundation (8)
  6. American Association for Cancer Research (6)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Journal Article

    Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Zimman, R.; Drake, L.; Riedel, E. R.; Hedvat, C. V.; more...
    British Journal of Haematology (2006)

    Fulltext@MSK | Save
  • Results of a phase I/II trial adding carmustine (300mg/m 2) to melphalan (200mg/m 2) in multiple myeloma patients undergoing autologous stem cell transplantation
    Journal Article

    Comenzo, R. L.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Dhodapkar, M.; Reich, L.; Teruya-Feldstein, J.; Fleisher, M.; Filippa, D.; Nimer, S. D.
    Leukemia (2006)

    Fulltext@MSK | Save
  • The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma
    Meeting Abstract

    Hassoun, H.; Reich, L.; Klimek, V. M.; Dhodapkar, M.; Cohen, A.; Kewalramani, T.; Riedel, E. R.; Hedvat, C. V.; Teruya-Feldstein, J.; Filippa, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement
    Meeting Abstract

    Comenzo, R. L.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Klimek, V.; Cohen, A. D.; Ferrand, S. K.; Dhodapkar, M.; Feldstein, J. T.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    Journal Article

    Stone, R. M.; DeAngelo, D. J.; Klimek, V.; Galinsky, I.; Estey, E.; Nimer, S. D.; Grandin, W.; Lebwohl, D.; Wang, Y. F.; Cohen, P.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
    Journal Article

    Kindler, T.; Breitenbuecher, F.; Kasper, S.; Estey, E.; Giles, F.; Feldman, E.; Ehninger, G.; Schiller, G.; Klimek, V.; Nimer, S. D.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
    Journal Article

    Wijermans, P. W.; Lübbert, M.; Verhoef, G.; Klimek, V.; Bosly, A.
    Annals of Hematology (2005)

    Fulltext@MSK | Save
  • Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: Report of a phase II trial
    Journal Article

    Gupta, S.; Zhou, P.; Hassoun, H.; Kewalramani, T.; Reich, L.; Costello, S.; Drake, L.; Klimek, V.; Dhodapkar, M.; Teruya-Feldstein, J.; more...
    Bone Marrow Transplantation (2005)

    Fulltext@MSK | Save
  • Clinical course and significance of the novel FLT3-Y842C mutation in a patient with AML treated with PKC412 monotherapy
    Meeting Abstract

    Kindler, T.; Breitenbuecher, F.; Kasper, S.; Estey, E.; Giles, F.; Feldman, E.; Ehninger, G.; Schiller, G.; Klimek, V.; Nimer, S. D.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Mechanisms of resistance to the FLT3-tyrosine kinase inhibitor PKC412 in patients with AML
    Meeting Abstract

    Heidel, F.; Breitenbuecher, F.; Kindler, T.; Solem, F. K.; Carius, B.; Thiede, H. M.; Cohen, P. S.; Roesel, J.; Estey, E. H.; Feldman, E.; more...
    Blood (2004)

    Fulltext@MSK | Save